TSY-310 / Almac Discovery, Formosa Pharmaceuticals - LARVOL DELTA

TSY-310, a novel bispecific EGFR×ROR1 ADC: Assessment of antitumor activity in heterogeneous breast tumors through enhanced internalization and bystander cytotoxicity. (ASCO 2026) - "These findings highlight TSY-310 as a first-in-class bispecific ADC capable of overcoming tumor heterogeneity through dual binding and bystander killing, supporting its potential as an effective therapeutic agent for heterogeneous solid tumors such as TNBC, where existing EGFR-targeted therapies have shown limited benefit."

ADC • Bispecific • Heterogeneity • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR • ROR1

Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting (PRNewswire) - "Highlights: (i) Superior Selectivity: Bispecific binding, enhancing internalization specifically in tumor cells co-expressing EGFR and ROR1; (ii) Enhanced Payload Delivery: Evidence of efficient lysosomal trafficking and the subsequent release of the cytotoxic payload; (iii) Bystander Efficacy: Eradication of neighboring antigen-negative tumor cells, a critical factor in treating complex, heterogeneous tumor environments."

Preclinical • Breast Cancer

ALM-401: A first-in-class next generation bispecific ADC configured to deliver superior efficacy in selected solid tumor indications (AACR 2025) - "This bsADC significantly outperforms a zilovertamab vedotin biosimilar, which exhibits an ORR of 22% (2/9) in these models at the same payload equivalent dose. ALM-401 has excellent plasma stability, a PK profile in line with approved ADCs, and good overall manufacturing and developability characteristics, with the potential to deliver significantly improved patient outcomes across a range of solid tumor indications with high unmet need."

ADC • Bispecific • Clinical • Late-breaking abstract • Gastric Cancer • Gastroesophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ROR1

Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors (PRNewswire) - "Taiwan-based Formosa Pharmaceuticals...announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, for exclusive rights to the commercialization of ALM-401, a first-in-class, bispecific antibody drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1...The licensing agreement includes upfront payment and development milestones, with additional considerations through approval and post-commercialization."

Licensing / partnership • Non Small Cell Lung Cancer • Solid Tumor